Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Lymphoma
77%
Mycobacterium Tuberculosis (M. tb)
71%
Follicular Lymphoma
54%
Overall Survival
53%
Immunochemotherapy
50%
Tuberculosis
50%
Active Tuberculosis
42%
Chemotherapy
41%
Progression-free Survival
40%
Epstein-Barr Virus
39%
Lung
34%
Pulmonary Granulomas
29%
Murine Model
29%
Chronic Lymphocytic Leukemia
29%
Prognostic Significance
28%
Necrosis
28%
C57BL
27%
Aggressive B-cell Lymphoma
25%
Aerosol
25%
High-grade B-cell Lymphoma
25%
Tumor
25%
Bacillary Load
24%
In Vivo murine Model
24%
Large B-cell Lymphoma
24%
Combined Antiretroviral Therapy (cART)
24%
Lymphoma Patients
24%
Hodgkin Lymphoma
24%
De Novo Diffuse Large B-cell Lymphoma
22%
Cervical mucus
22%
Neoadjuvant Chemotherapy
22%
Siglec
22%
MYC Protein
22%
Plasmablastic Lymphoma
22%
Granuloma
22%
Protein Expression
21%
Prognostic Impact
21%
People Living with HIV (PLHIV)
21%
Burkitt
20%
HIV Infection
20%
Foamy Macrophages
20%
B-cell Lymphoma 2 (Bcl-2)
20%
Time to Progression
19%
Mycobacterium Tuberculosis Infection
19%
Mouse Strain
18%
Improved Survival
18%
Macrophages
18%
AIDS/HIV
18%
MYC Translocation
17%
Flow Cytometry
17%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
89%
Human Immunodeficiency Virus
80%
Epstein Barr Virus
43%
B-Cell Lymphoma
41%
B Cell
34%
B-Cell Chronic Lymphocytic Leukemia
33%
Follicular Lymphoma
32%
Non-Hodgkin Lymphoma
31%
Tumor
29%
Diseases
29%
Neoplasm
28%
Overall Survival
27%
Biological Marker
25%
Progression Free Survival
25%
Breast Cancer
24%
Hodgkin's Lymphoma
24%
Protein Expression
22%
Neoadjuvant Chemotherapy
22%
Sialoadhesin
22%
Lymphocyte
22%
Plasmablastic Lymphoma
22%
Burkitt's Lymphoma
20%
MALT Lymphoma
17%
Rituximab
17%
Immunoglobulin
17%
Mycobacterium Tuberculosis
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Lymphoproliferative Disease
16%
Prognostic Factor
15%
Antiretroviral Therapy
15%
Low Drug Dose
15%
Differential Diagnosis
15%
Flow Cytometry
15%
Lung
15%
Immunohistochemistry
14%
Infection
13%
Virus
13%
Messenger RNA
13%
Necrosis
11%
Lung Granuloma
11%
Monoclonal B Cell Lymphocytosis
11%
Upper Urinary Tract
11%
BRCA1
11%
Lung Adenocarcinoma
11%
Triple Negative Breast Cancer
11%
Histiocytosis
11%
Beta 2 Microglobulin
11%
Acetylsalicylic Acid
11%
Wedge Resection
11%
Human Herpesvirus 8
11%
Immunology and Microbiology
Infection
83%
B Cell
73%
Mycobacterium Tuberculosis
71%
Granuloma
47%
Human Immunodeficiency Virus
37%
Progression Free Survival
33%
Overall Survival
31%
Macrophage
30%
Low Drug Dose
26%
C3HeB/Fe Mouse
22%
Sialoadhesin
22%
Uterine Cervix Mucosa
22%
Epstein Barr Virus
22%
Neutrophil
17%
C57BL 6 Mouse
17%
Human Immunodeficiency Virus Infection
17%
Gene Mutation
17%
Cytokine
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Tumor Necrosis Factor
15%
Interleukin 6
15%
Mycobacteria
14%
Rituximab
14%
Human Immunodeficiency Virus 1
14%
Bacterial Load
14%
Protein Expression
13%
T Cell
13%
Mouse Strain
12%
Minipig
11%
Glycosyltransferase
11%
Regulatory T Cell
11%
Innate Immune System
11%
Intestine Flora
11%
Lymphoproliferative Disorders
11%
DBA 2 Mouse
11%
Dendritic Cell
11%
Immunotherapy
11%
Inflammation Response
11%
Intravenous Immunoglobulin
11%
Interferon Regulatory Factor 4
11%
Cancer Immunotherapy
11%
Colorectal Carcinoma
11%
Muscle
11%
Acetic Acid Derivative
11%
Susceptibility
11%
Memory T Cell
11%
Cell Cycle
11%
Lymphocyte
9%
CD4
9%
Interleukin 10
9%
